WGS
GeneDx Holdings Corp.
71.50$
-6.2%
vs. previous close
Closing price · As of: Oct 6, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +0.4% | -5.8% | -1.4% | +5.1% | +2.6% | +6.4% | +3.9% | +6.5% | +15.4% | -11.2% | -4.9% | |
| – | +6.1% | -10.4% | -0.8% | +14.7% | +6.4% | +14.1% | -9.3% | +16.0% | +12.9% | +0.9% | -9.0% | |
| – | +14.1% | -16.1% | -33.0% | +3.2% | +47.2% | +17.0% | -25.7% | +29.5% | +9.4% | -10.5% | -35.8% | |
| – | +13.9% | -13.2% | -5.4% | +9.0% | +21.2% | +12.7% | -15.5% | +15.3% | +10.4% | -0.3% | -22.3% | |
| – | +1.3% | -11.9% | -9.4% | +46.9% | -2.2% | +22.4% | +4.3% | +26.9% | +22.0% | +3.4% | +8.7% | |
| – | -6.1% | +32.3% | -11.1% | +4.3% | -1.1% | +18.9% | -5.8% | -11.4% | +32.0% | -12.3% | +45.6% | |
| – | – | – | – | – | – | – | – | -1.0% | +5.6% | -87.9% | +0.0% | |
| – | -2.0% | -2.0% | -2.1% | -2.1% | -2.2% | -2.2% | +13.9% | -2.3% | -2.4% | -14.0% | -2.5% | |
| – | +17.0% | -1.8% | +4.1% | +4.8% | -14.8% | +8.6% | -1.2% | +8.0% | +29.9% | -3.8% | -5.9% | |
| – | -14.0% | -13.7% | +34.6% | +13.3% | -29.1% | +26.9% | +2.7% | +22.7% | +24.3% | -19.5% | -14.8% | |
| – | +6.9% | +114.4% | -55.0% | -7.6% | -9.8% | -6.4% | -1.3% | +43.7% | +102.0% | -42.7% | +11.3% | |
| – | -33.4% | -7.4% | -14.2% | +10.9% | -11.8% | +99.3% | -77.8% | -25.3% | -6.4% | +353.8% | -53.9% | |
| – | +770.6% | -0.7% | -0.3% | -0.2% | -0.2% | -0.2% | -0.2% | -0.2% | -6.6% | +100.8% | +0.1% | |
| – | -10.3% | -9.1% | -6.4% | +5.4% | +19.9% | +5.0% | +7.7% | +5.5% | +5.4% | -17.5% | -3.9% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.7% | +0.3% | +2.1% | +1.8% | -0.4% | +4.3% | +5.7% | -3.2% | -6.6% | +9.1% | +1.3% |
Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.